Lauren Sabella has been Chief Commercial Officer at Acorda since February 2015. Ms. Sabella joined Acorda in 2010 as Executive Vice President of Commercial Development, with responsibility for the commercial launch of Ampyra, including Marketing, Sales, Market Access, Trade Relations and Commercial Operations. Before joining Acorda, Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and Vice President of Commercial Development at Altus Pharmaceuticals, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as Vice President of Sales, Eastern Zone, where she led the successful sales launch of Spiriva® (tiotropium bromide) and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of 

 Lauren Sabella has been Chief Commercial Officer at Acorda since February 2015. Ms. Sabella joined Acorda in 2010 as Executive Vice President of Commercial Development, with responsibility for the commercial launch of Ampyra, including Marketing, Sales, Market Access, Trade Relations and Commercial Operations. Before joining Acorda, Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and Vice President of Commercial Development at Altus Pharmaceuticals, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as Vice President of Sales, Eastern Zone, where she led the successful sales launch of Spiriva® (tiotropium bromide) and ran both Primary Care and Specialty Divisions, including Neurolog